 Neoplasm Metastasis
"Neoplasm Metastasis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
| Descriptor ID |
D009362
|
| MeSH Number(s) |
C04.697.650 C23.550.727.650
|
| Concept/Terms |
Neoplasm Metastasis- Neoplasm Metastasis
- Metastases, Neoplasm
- Neoplasm Metastases
- Metastasis
- Metastases
- Metastasis, Neoplasm
|
Below are MeSH descriptors whose meaning is more general than "Neoplasm Metastasis".
Below are MeSH descriptors whose meaning is more specific than "Neoplasm Metastasis".
This graph shows the total number of publications written about "Neoplasm Metastasis" by people in this website by year, and whether "Neoplasm Metastasis" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 5 | 5 | | 1995 | 0 | 1 | 1 | | 1996 | 1 | 4 | 5 | | 1997 | 0 | 1 | 1 | | 1998 | 0 | 4 | 4 | | 2000 | 0 | 5 | 5 | | 2001 | 1 | 1 | 2 | | 2002 | 1 | 2 | 3 | | 2003 | 4 | 6 | 10 | | 2004 | 1 | 9 | 10 | | 2005 | 1 | 9 | 10 | | 2006 | 0 | 6 | 6 | | 2007 | 1 | 9 | 10 | | 2008 | 1 | 5 | 6 | | 2009 | 5 | 16 | 21 | | 2010 | 4 | 15 | 19 | | 2011 | 1 | 14 | 15 | | 2012 | 2 | 14 | 16 | | 2013 | 2 | 17 | 19 | | 2014 | 1 | 20 | 21 | | 2015 | 4 | 19 | 23 | | 2016 | 3 | 29 | 32 | | 2017 | 2 | 32 | 34 | | 2018 | 0 | 24 | 24 | | 2019 | 2 | 16 | 18 | | 2020 | 2 | 16 | 18 | | 2021 | 0 | 8 | 8 | | 2022 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Neoplasm Metastasis" by people in Profiles.
-
Ghosh JC, Perego M, Agarwal E, Bertolini I, Wang Y, Goldman AR, Tang HY, Kossenkov AV, Landis CJ, Languino LR, Plow EF, Morotti A, Ottobrini L, Locatelli M, Speicher DW, Caino MC, Cassel J, Salvino JM, Robert ME, Vaira V, Altieri DC. Ghost mitochondria drive metastasis through adaptive GCN2/Akt therapeutic vulnerability. Proc Natl Acad Sci U S A. 2022 02 22; 119(8).
-
Eggermont AM, Ascierto PA, Khushalani NI, Schadendorf D, Boland G, Weber J, Lewis KD, Johnson D, Rivalland G, Khattak A, Majem M, Gogas H, Long GV, Currie SL, Chien D, Tagliaferri MA, Carlino MS, Diab A. PIVOT-12: a?phase III?study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence. Future Oncol. 2022 Mar; 18(8):903-913.
-
Colton MD, Tompkins K, O'Donnell E, Aisner D, Lieu CH, Konnick EQ, Fishbein L. Case of Metastatic Pheochromocytoma and Meningiomas in a Patient With Lynch Syndrome. JCO Precis Oncol. 2022 01; 6:e2100251.
-
Saad F, Efstathiou E, Attard G, Flaig TW, Franke F, Goodman OB, Oudard S, Steuber T, Suzuki H, Wu D, Yeruva K, De Porre P, Brookman-May S, Li S, Li J, Thomas S, Bevans KB, Mundle SD, McCarthy SA, Rathkopf DE. Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2021 11; 22(11):1541-1559.
-
Siu HWD, Tebbutt N, Chantrill L, Karapetis C, Steer C, Wilson K, Espinoza D, Bailey L, Yip S, Cuff J, Pavlakis N, Thavaneswaran S, Briscoe K, Srivastav R, Shannon J, Segelov E, Tie J, Caird S, Francesconi A, Price T, Wuttke M, Ladwa R, Sjoquist K, Burge M. MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG). BMC Cancer. 2021 Aug 18; 21(1):932.
-
Pin F, Prideaux M, Huot JR, Essex AL, Plotkin LI, Bonetto A, Bonewald LF. Non-bone metastatic cancers promote osteocyte-induced bone destruction. Cancer Lett. 2021 11 01; 520:80-90.
-
Subbiah V, Hu MI, Wirth LJ, Schuler M, Mansfield AS, Curigliano G, Brose MS, Zhu VW, Leboulleux S, Bowles DW, Baik CS, Adkins D, Keam B, Matos I, Garralda E, Gainor JF, Lopes G, Lin CC, Godbert Y, Sarker D, Miller SG, Clifford C, Zhang H, Turner CD, Taylor MH. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol. 2021 08; 9(8):491-501.
-
Chang E, Joel MZ, Chang HY, Du J, Khanna O, Omuro A, Chiang V, Aneja S. Comparison of radiomic feature aggregation methods for patients with multiple tumors. Sci Rep. 2021 05 07; 11(1):9758.
-
Fishbein L, Del Rivero J, Else T, Howe JR, Asa SL, Cohen DL, Dahia PLM, Fraker DL, Goodman KA, Hope TA, Kunz PL, Perez K, Perrier ND, Pryma DA, Ryder M, Sasson AR, Soulen MC, Jimenez C. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma. Pancreas. 2021 04 01; 50(4):469-493.
-
Dziadziuszko R, Krebs MG, De Braud F, Siena S, Drilon A, Doebele RC, Patel MR, Cho BC, Liu SV, Ahn MJ, Chiu CH, Farago AF, Lin CC, Karapetis CS, Li YC, Day BM, Chen D, Wilson TR, Barlesi F. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. J Clin Oncol. 2021 04 10; 39(11):1253-1263.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|